New Catalogue for 2022

We’re pleased to share our new medical brochure for 2022. Over the past year we have added new products to our existing ranges, including dozens of new drugs of abuse tests and rapid lateral flow tests, as well as our new range of bacterial typing anti-sera and the virusPHIX molecular transport medium for virus inactivation [...]

2022-01-14T11:26:37+00:00January 6th, 2022|

Christmas Opening Hours

As another year draws to an end, we would like to take the opportunity to thank all of our customers for their continued support over the past year and wish everyone a very merry Christmas. Our offices will be closed from the 24th December and will reopen on the 4th January. Any orders placed after [...]

2021-12-16T09:30:32+00:00December 16th, 2021|

QCMD to use virusPHIX-P9™ in its SARS-CoV-2 antigen EQA scheme

QCMD will use the universal biological sample stabilisation virusPHIX-P9™ as the matrix within its forthcoming SARS-CoV-2 antigen EQA pilot scheme. Studies have proven that virusPHIX-P9™ is both capable of inactivating SARS-CoV-2 as well as stabilizing clinical samples at ambient temperatures. Extensive testing at QCMD has shown that virusPHIX-P9™ is compatible with a variety of SARS-CoV-2 [...]

2021-03-10T13:56:11+00:00March 10th, 2021|

Rapid Labs launch virusPHIX range of virus inactivation medium with RNAssist Ltd.

RNAssist (Cambridge UK) and Rapid Labs Ltd (Colchester, UK) have launched the virusPHIX™ range of virus inactivating and RNA stabilising transport media, following successful SARS-CoV-2 inactivation. virusPHIX™ is a novel RNA stabiliser and virus inactivation medium based on technology developed by RNAssist Limited (Cambridge, UK). It has been shown to stabilise viral RNA for up [...]

2021-03-04T11:03:48+00:00February 4th, 2021|

Merry Christmas from Rapid Labs

We would like to wish all our customers a very merry Christmas and a happy new year. Please note that our offices close on Thursday 24th December and will reopen on Monday 4th January. After what has been a tough year for everyone, we look forward to a bright and healthy 2021.  

2020-12-15T14:54:10+00:00December 15th, 2020|

Rapid Labs Ltd secure £80,000 grant from Tendring District Council

Rapid Labs have been awarded an £80,000 grant from Tendring District Council to increase production capacity at their biomedical facility in Little Bentley. The grant has contributed towards the cost of a new ISO 8 clean room facility, which is primarily being used for the manufacture and development of a novel RNA stabiliser and virus [...]

2020-08-17T10:44:58+01:00August 17th, 2020|

Rapid Labs become members of the British In Vitro Diagnostics Association (BIVDA)

We are pleased to announce that Rapid Labs Ltd have been awarded membership of the British In Vitro Diagnostics Association (BIVDA). BIVDA is the national industry association for the manufacturers and distributors of IVD products in the UK and currently represent more than 95% of the industry and over a hundred organisations ranging from British [...]

2020-07-30T16:47:10+01:00July 30th, 2020|

Zika Virus Successfully Inactivated Using VivoPHIX

The Pasteur Institute has successfully demonstrated inactivation of the Zika Virus using vivoPHIX™: To determine the ability of vivoPHIX™ to inhibit ZIKV in mosquito tissue sample, ZIKV-infected mosquito midguts were dissected at 6 dpi. Mosquito midguts were then chopped into 3-4 small pieces then transfer into vivoPHIX™. Samples were then treated at 4 degree Celsius [...]

2020-06-17T16:16:26+01:00June 17th, 2020|

New virusPHIX Brochure

Following last week's announcement regarding the development of our new reagent, virusPHIX™ and call for trial sites to evaluate it's suitability for COVID-19 testing, we are pleased to share our new product brochure. The virusPHIX™ brochure includes information about its key features, list of viruses it has successfully inactivated, preliminary data regarding inactivation of SARS-CoV-2 [...]

2020-05-27T10:57:32+01:00May 27th, 2020|

Rapid Labs and RNAssist announce development and trials of SARS-COV-2 viral transport medium

May 2020 Press Release Rapid Labs Ltd (Essex, UK), RNAssist (Cambridge, UK) and Qnostics (Glasgow, UK) are currently developing and seeking trial sites to validate the virusPHIX™ RNA stabilisation, cell fixative and virus inactivation reagent for SARS-CoV-2 testing on nasopharangeal swab samples and saliva/sputum samples.  Offer; A universal sample collection tube for liquid samples including; [...]

2020-05-20T11:09:18+01:00May 20th, 2020|